The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.
AML
CAR
CD123
T cell therapy
chimeric antigen receptor
immunotherapy
leukemia
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
11 Sep 2020
11 Sep 2020
Historique:
received:
03
06
2020
accepted:
25
06
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with refractory/recurrent disease. We generated five lentiviral vectors encoding CD20, which may serve as a target for CAR T cell depletion, and 2
Identifiants
pubmed: 32775492
doi: 10.1016/j.omtm.2020.06.024
pii: S2329-0501(20)30148-0
pmc: PMC7393323
doi:
Types de publication
Journal Article
Langues
eng
Pagination
571-581Informations de copyright
© 2020 The Author(s).
Références
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
J Immunother Cancer. 2019 Aug 7;7(1):209
pubmed: 31391096
Cell. 2017 Jun 29;170(1):142-157.e19
pubmed: 28648661
Blood. 2014 Apr 10;123(15):2343-54
pubmed: 24596416
Cancer Immunol Res. 2019 May;7(5):759-772
pubmed: 30890531
J Immunother. 2007 Sep;30(6):607-13
pubmed: 17667524
Nat Med. 2019 Jun;25(6):947-953
pubmed: 31011207
Oncoimmunology. 2016 Nov 8;5(12):e1253656
pubmed: 28180032
Blood. 2017 Apr 27;129(17):2395-2407
pubmed: 28246194
Cancer Immunol Res. 2015 Apr;3(4):368-79
pubmed: 25576337
J Clin Oncol. 2015 Sep 20;33(27):2949-62
pubmed: 26304895
Clin Cancer Res. 2019 Sep 1;25(17):5329-5341
pubmed: 31110075
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Cancer Immunol Res. 2017 Oct;5(10):860-870
pubmed: 28821531
Haematologica. 2009 Sep;94(9):1316-20
pubmed: 19734426
Blood. 2019 Aug 15;134(7):626-635
pubmed: 31262783
J Immunother. 2005 May-Jun;28(3):203-11
pubmed: 15838376
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708
pubmed: 30413526
Blood Cancer J. 2014 Jun 13;4:e218
pubmed: 24927407
Cell Death Dis. 2019 Jun 17;10(7):476
pubmed: 31209210
Blood. 2013 Oct 31;122(18):3138-48
pubmed: 24030378
Immunity. 2016 Feb 16;44(2):380-90
pubmed: 26885860
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025
pubmed: 30979735
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
J Clin Invest. 2008 Jan;118(1):294-305
pubmed: 18060041
PLoS Comput Biol. 2012;8(2):e1002388
pubmed: 22383868
Blood. 2013 Feb 14;121(7):1165-74
pubmed: 23243285
Mol Ther. 2018 Jan 3;26(1):280-288
pubmed: 28970045
Mol Ther. 2018 Dec 5;26(12):2727-2737
pubmed: 30309819
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Clin Adv Hematol Oncol. 2018 Oct;16(10):664-666
pubmed: 30543595
Cancer Discov. 2017 Nov;7(11):1306-1319
pubmed: 28801306
Cell Rep. 2017 Oct 3;21(1):17-26
pubmed: 28978471
J Gene Med. 2013 Feb;15(2):78-82
pubmed: 23322669
Leukemia. 2015 Feb;29(2):387-95
pubmed: 24888271
Clin Cancer Res. 2019 Feb 15;25(4):1142-1146
pubmed: 30309857
Blood Adv. 2018 Apr 24;2(8):848-858
pubmed: 29661755
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Cancer Cell. 2017 Oct 9;32(4):506-519.e5
pubmed: 29017060
Blood. 2011 Apr 21;117(16):4304-14
pubmed: 21304103
Mol Ther. 2016 Sep 29;24(9):1615-26
pubmed: 27401038
Cancer Discov. 2020 May;10(5):702-723
pubmed: 32193224
Mol Ther. 2017 Sep 6;25(9):2202-2213
pubmed: 28676343
Clin Cancer Res. 2013 Jun 15;19(12):3153-64
pubmed: 23620405